The European Commission Has Approved Mirati Therapeutics' Krazati (Adagrasib) For KRASG12C-mutated Advanced Non-small Cell Lung Cancer And Disease Progression After At Least One Prior Systemic Therapy
Portfolio Pulse from Benzinga Newsdesk
The European Commission has granted approval to Mirati Therapeutics' Krazati (Adagrasib) for the treatment of KRASG12C-mutated advanced non-small cell lung cancer in patients who have undergone at least one prior systemic therapy. This marks a significant regulatory milestone for Mirati Therapeutics, potentially impacting its market presence in Europe.
January 10, 2024 | 1:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Mirati Therapeutics' Krazati has been approved by the European Commission for advanced non-small cell lung cancer treatment, which could lead to increased market penetration and revenue in Europe.
The approval of Krazati in the European market is a significant event for Mirati Therapeutics as it opens up a new market for the drug. This could lead to increased sales and revenue, positively influencing the company's financial performance in the short term. The news is directly related to the company's core business and is likely to be viewed positively by investors.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100